| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/02/2001 | US6169087 An enzyme inhibitor for treating type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance, obesity, autoimmune diseases, diseases with dysfunctions of the coagulation system, allergic diseases, cancer, psoriasis |
| 01/02/2001 | US6169084 2-methyl-thieno-benzodiazepine formulation |
| 01/02/2001 | US6169083 Administering an l-carnosine zinc salt or l-carnosine-zinc complex; treating the side effect of cancer chemotherapy or radiotherapy |
| 01/02/2001 | US6169082 Salts of 8,9-dehydroestrone sulfate ester |
| 01/02/2001 | US6169079 An antisense oligonucleotides designed to hybridize to the mrna encoding intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, for treating inflammation |
| 01/02/2001 | US6169075 Antitumor agent inhibiting the proliferation of a range of rapidly dividing tumour cells like melanoma and/or lymphoma cells |
| 01/02/2001 | US6168950 Compound 8 to 30 nucleotides in length which specifically hybridizes and inhibits gene expression of human mitogen-activated protein kinase kinase kinase 1; anticarcinogenic/antiproliferative agents |
| 01/02/2001 | US6168946 gp75 as a tumor vaccine for melanoma |
| 01/02/2001 | US6168942 Attenuated forms of bovine viral diarrhea virus |
| 01/02/2001 | US6168809 Cosmetic composition can be used for applying make-up to or removing make-up from sensitive eyes; strontium salt |
| 01/02/2001 | US6168806 Orally administrable nifedipine pellet and process for the preparation thereof |
| 01/02/2001 | US6168805 Aqueous process for manufacturing paroxetine solid dispersions |
| 01/02/2001 | US6168802 In the last few years there has been considerable interest among athletes in creatine, which occurs abundantly in skeletal muscle. |
| 01/02/2001 | US6168799 β-D-glucan topical composition |
| 01/02/2001 | US6168792 Materials and methods for detection and treatment of immune system dysfunctions |
| 01/02/2001 | US6168787 Pluripotent vaccine against enveloped viruses |
| 01/02/2001 | US6168782 Elastomeric silicone containing an active ingredient |
| 01/02/2001 | US6168776 Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| 01/02/2001 | US6167887 Selected C-10 perfluorinated hydrocarbons for liquid ventilation and artificial blood |
| 01/02/2001 | CA2184693C Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide derivatives |
| 01/02/2001 | CA2184692C Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide disulfide derivatives |
| 01/02/2001 | CA2183313C Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase |
| 01/02/2001 | CA2174034C Novel tricyclic amides, processes for their preparation and the pharmaceutical compositions which contain them |
| 01/02/2001 | CA2154721C 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| 01/02/2001 | CA2106172C Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the treatment of restenosis associated with coronary intervention |
| 01/02/2001 | CA2095613C Substituted 1, 3-oxathiolanes and substituted 1, 3-dithiolanes with antiviral properties |
| 01/02/2001 | CA2094424C Method of treating osteoporosis with 1.alpha.,24(r)-dihydroxy-22(e)-dehydro-vitamin d3 |
| 01/02/2001 | CA2075060C Novel vehicle gases and their use in medical preparations |
| 01/02/2001 | CA2071837C Vitamin-mineral treatment methods and compositions |
| 01/02/2001 | CA2068064C Fibrinogen receptor antagonists |
| 01/02/2001 | CA2054850C Cyclic imino derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
| 01/02/2001 | CA2027596C Compositions containing hyaluronic acid complexes with zinc or cobalt |
| 01/02/2001 | CA2027593C Composition with antiaggreting action on platelet, for therapeutic uses |
| 01/02/2001 | CA2025070C Recombinant aprotinin variants genetically engineered process for the microbial preparation of homgeneously processed aprotinin variants and the therapeutic use thereof |
| 01/02/2001 | CA2013449C Antibacterial 5-alkylquinolonecarboxylic acids |
| 01/02/2001 | CA2013166C Suppression of parathyroid hormone synthesis and secretion |
| 01/02/2001 | CA2009604C Diaryl-substituted heterocyclic compounds, their preparation and drugs and cosmetics obtained therefrom |
| 01/02/2001 | CA2001572C Compositions for treating tobacco withdrawal symptoms |
| 01/02/2001 | CA1341162C Sbustituted aminomethyltetralins and their heterocyclic analogues |
| 01/02/2001 | CA1341161C Quinolone- and naphthyridone carboxylic acid derivatives, process for their production, antibacterial compositions and feed additives containing them |
| 01/02/2001 | CA1341159C Pure enantiomers of 4,5-disubstituted .alpha.-butyrolactams, process for their preparation, and their use |
| 12/30/2000 | CA2313131A1 Compositions and treatment for diabetic complications |
| 12/30/2000 | CA2313105A1 Treatment for diabetic complications |
| 12/30/2000 | CA2313063A1 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| 12/30/2000 | CA2312989A1 Combination therapy for the treatment of migraine |
| 12/30/2000 | CA2312633A1 Combination therapy for the treatment of migraine |
| 12/30/2000 | CA2312631A1 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine |
| 12/29/2000 | CA2283352A1 Methods of use of gemifloxacin compounds against fluoroquinolone resistant streptococcus pneumoniae bacteria |
| 12/29/2000 | CA2283141A1 Methods of use of gemifloxacin compounds against fluoroquinolone resistant streptococcus pneumoniae bacteria |
| 12/28/2000 | WO2000078972A2 Regulation with binding cassette transporter protein abc1 |
| 12/28/2000 | WO2000078971A2 Atp binding cassette transporter protein abc1 popypeptides |
| 12/28/2000 | WO2000078970A1 Nucleic and proteinic acids corresponding to human gene abc1 |
| 12/28/2000 | WO2000078953A2 Human transport proteins |
| 12/28/2000 | WO2000078941A2 Methods and products for manipulating uncoupling protein expression |
| 12/28/2000 | WO2000078939A2 Vectors for the treatment of tumors by gene therapy |
| 12/28/2000 | WO2000078810A1 Surfactant protein c esters |
| 12/28/2000 | WO2000078794A1 Cysteinyl protease inhibitors |
| 12/28/2000 | WO2000078789A1 Aromatic and heterocyclic derivatives of phytosterols and/or phytostanols for use in treating or preventing cardiovascular disease |
| 12/28/2000 | WO2000078779A2 N-pyrazole a2a receptor agonists |
| 12/28/2000 | WO2000078778A2 C-pyrazole a2a receptor agonists |
| 12/28/2000 | WO2000078777A1 Propargyl phenyl ether a2a receptor agonists |
| 12/28/2000 | WO2000078776A2 Thiophene a2a receptor agonists |
| 12/28/2000 | WO2000078772A2 Antibiotic agents |
| 12/28/2000 | WO2000078768A1 Potassium channel openers |
| 12/28/2000 | WO2000078767A1 Thienopyrimidines as phosphodiesterase inhibitors |
| 12/28/2000 | WO2000078765A2 CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS |
| 12/28/2000 | WO2000078762A1 Indoloazepines as vasopressin receptor antagonists |
| 12/28/2000 | WO2000078760A1 Process for preparing sildenafil, and troche which comprises sildenafil and apomorphine |
| 12/28/2000 | WO2000078759A1 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists |
| 12/28/2000 | WO2000078757A1 Inhibitors of il-12 production |
| 12/28/2000 | WO2000078756A1 Thiophene-ethyl thiourea compounds and their use in the treatment of hiv |
| 12/28/2000 | WO2000078755A1 Thiophene-ethyl thiourea compounds and use in the treatment of hiv |
| 12/28/2000 | WO2000078753A1 Process for the preparation of paroxetine and structurally related compounds |
| 12/28/2000 | WO2000078751A2 Compounds for use in treatment of neurological disorders |
| 12/28/2000 | WO2000078750A1 New pharmaceutically active compounds |
| 12/28/2000 | WO2000078748A1 Quinoline derivatives as antibacterials |
| 12/28/2000 | WO2000078746A1 Antiviral agents |
| 12/28/2000 | WO2000078745A2 Crystalline form of (r)-2-[[[3-methyl- 4- (2,2,2,- trifluoroethoxy) -2- pyridinyl] methyl] sulfinyl] -1h-benzimidazole |
| 12/28/2000 | WO2000078744A1 Thiochroman derivatives against neurological disorders |
| 12/28/2000 | WO2000078742A1 Chroman derivatives against neurological disorders |
| 12/28/2000 | WO2000078738A1 Melamine derivatives as potent anti-cancer agents |
| 12/28/2000 | WO2000078736A1 1,4-diazacycloheptane derivatives as neuroprotective agents |
| 12/28/2000 | WO2000078735A1 Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof |
| 12/28/2000 | WO2000078732A1 Halopyrimidines |
| 12/28/2000 | WO2000078731A1 5-cyano-2-aminopyrimidine derivatives |
| 12/28/2000 | WO2000078728A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
| 12/28/2000 | WO2000078721A1 Phenetyl-thiourea compounds for treating hiv infections |
| 12/28/2000 | WO2000078718A1 4-aminopiperidine derivatives of tetrahydronaphthalene, chromans and thiochromans |
| 12/28/2000 | WO2000078716A1 α1B-ADRENERGIC RECEPTOR ANTAGONISTS |
| 12/28/2000 | WO2000078708A1 Substituted benzamide inhibitors of rhinovirus 3c protease |
| 12/28/2000 | WO2000078697A2 High molecular weight primary aliphatic alcohols obtained from beeswax and pharmaceutical use thereof |
| 12/28/2000 | WO2000078396A2 Topical ophthalmic mast cell stabilizers for treating allergic eye diseases |
| 12/28/2000 | WO2000078355A2 Biologically active materials |
| 12/28/2000 | WO2000078352A1 Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method |
| 12/28/2000 | WO2000078351A1 Osteogenesis promoters |
| 12/28/2000 | WO2000078350A1 Remedies for skin ulcer |
| 12/28/2000 | WO2000078343A2 Method for treating chronic hbv infection |
| 12/28/2000 | WO2000078341A1 A method for the prophylaxis and/or treatment of medical disorders |
| 12/28/2000 | WO2000078326A1 Method and composition for preventing or treating adverse physiological effects associated with cardiac disease |
| 12/28/2000 | WO2000078325A1 Synergistic compositions containing lycopene and silymarin for treatment of liver disease |